The U.S. Department of State on Thursday announced plans to bring lenacapavir — a potentially game-changing innovation for HIV prevention — to 2 million people by 2028.
Through the U.S. President’s Emergency Plan for AIDS Relief, or PEPFAR, the State Department will partner with countries with the largest burden of HIV and AIDS “over the coming months to co-develop strategies for distributing lenacapavir, with a focus on preventing mother-to-child transmission,” according to the news release.
Gilead Sciences, the company that developed the drug, is offering lenacapavir “at no profit” as part of the initiative, said its chairman and CEO, Daniel O’Day.